...companies - SNUS, Bracco Diagnostics Inc. (Milan, Italy), DuPont Merck Pharmaceutical Co. (Wilmington, Del.) and ImaRx...

...by late next year and launch it "shortly" thereafter. In 2008, Microbix acquired Kinlytic from ImaRx Therapeutics Inc....

...was only marketed for PE, were about $40 million. In 2008, Microbix acquired Kinlytic from ImaRx Therapeutics Inc....

...a greater number of sICH events in patients receiving SonoLysis (see BioCentury, Jan. 14, 2008). ImaRx...
...dose in future trials. Data were presented at the International Stroke Conference in San Diego. ImaRx Therapeutics Inc....

...Microbix acquired ImaRx's Kinlytic urokinase business at a much lower price than specified in the companies'...
...price than specified in the companies' previous agreement. Microbix paid $2 million in cash, and ImaRx...
...the business for $12 million up front and $5 million in milestones. On May 13, ImaRx...

...to acquire ImaRx’s Kinlytic urokinase business because Microbix could not raise sufficient funds, and because ImaRx...
...urokinase inventory. As a result, ImaRx terminated all employees except President and CEO Brad Zakes. ImaRx...
...nanobubbles plus ultrasound that is in Phase I/II trials to treat stroke. At March 31, ImaRx...

...The companies signed a letter of intent for Microbix to acquire ImaRx’s Kinlytic urokinase (formerly Abbokinase...
...for $12 million up front, plus up to $5 million for an inventory stability milestone. ImaRx...
...in 1978 to treat pulmonary embolism (PE). ImaRx’s 2007 sales of urokinase were $7.8 million. ImaRx...

...from Abbott after paying the remaining balance of a $15 million promissory note to Abbott. ImaRx...
...Abbott in 2006. The thrombolytic agent is approved to treat pulmonary embolism (PE). In January, ImaRx...
...Inc. (TSE:MBX, Toronto, Ontario) rights to develop urokinase for other indications (see BioCentury, Jan. 28). ImaRx Therapeutics Inc....

...urokinase program. The company’s Abbokinase urokinase is approved to treat pulmonary embolism (PE). Last month, ImaRx...
...BioCentury, Jan. 28). ImaRx acquired Abbokinase from Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) in 2006. ImaRx Therapeutics Inc....

...The companies signed a letter of intent for Microbix to develop ImaRx's Abbokinase urokinase for certain...
...for which the thrombolytic is in preclinical development. Other licensed indications include cancer and ophthalmology. ImaRx...
...is eligible for royalties. Abbokinase was approved in 1978 to treat pulmonary embolism (PE), and ImaRx...